Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T22:18:07.236Z.
Calculation as of: 2026-10-06T22:18:07.236Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $870.81M | N/A | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | 4.06 | 3.58 | 4.12 | 5.15 |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | 0.32 | 0.49 | 0.82 | 1.32 |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 4.87 | 37.06 | 52.92 | 39.21 |
| Alumis Inc. (ALMS)vs › | $855.38M | 115.62 | 174.59 | 129.38 | 129.38 |
| Bioventus Inc. (BVS)vs › | $887.50M | 1.53 | 1.18 | 0.98 | 0.92 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 3.08 | 2.48 | 2.06 | 2.27 |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | 5.27 | 3.19 | 4.02 | 10.18 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
